Australia : Consultation: Proposed GMP exemption for certain bacteriophage manufacture

-

Consultation: Proposed GMP exemption for certain bacteriophage manufacture

Overview

The Therapeutic Goods Administration (TGA) is seeking your feedback on a proposed time-limited GMP exemption for manufactures of personalised bacteriophage therapy products (BTPs). 

In the last 5-10 years, increasing anti-microbial resistance (AMR) and medical device-related infections have led to the resurgence in interest from researchers and clinicians seeking access to experimental therapies for their patients. Unapproved BTPs are increasingly being considered. However, BTPs have not had their efficacy, safety or quality assessed by the TGA and are currently being supplied as unapproved goods under the Special Access Scheme (SAS) and Clinical Trial Notification (CTN) scheme provisions.

The manufacturing process of BTPs is multifaceted and complex and there are no Good Manufacturing Practice (GMP) licensed bacteriophage facilities in Australia. The TGA supports the development of innovative therapies, and this proposal aims to support the bacteriophage sector whilst it upgrades manufacturing facilities, develop standards and collect clinical data to support the safe use of these products for patients. Inhibiting the domestic manufacture may force medical providers to import BTPs from overseas which may significantly increase the timeframe for patients to receive treatment and would not necessarily ensure a higher quality product. 

The TGA wants to ensure regulation of unapproved BTPs remains fit-for-purpose and considers patients’ need to access as well as the quality and safety of treatments administered. Feedback obtained from this consultation will inform amendments to the Regulations. 

Submissions must be received by 11:59pm on 12 November 2025 and should be provided through the consultation hub - external site.

Consultation document

Submissions must be received by 11:59pm 13 November 2025 Consultation on including a time-limited GMP exemption for manufacturing of personalised bacteriophages - external site.

We aim to provide documents in an accessible format. If you're having problems using this document, please contact TGA.Scientific@health.gov.au.



Article taken from, copyright belongs to : https://www.tga.gov.au/resources/consultation/consultation-proposed-gmp-exemption-certain-bacteriophage-manufacture

Comments

Post a Comment

Popular posts from this blog

History Part 12 : Post-War Stagnation and Phage Therapy’s Marginalization in the West (1945–1980s)

-
Image
Post-War Stagnation and Phage Therapy’s Marginalization in the West (1945–1980s) The period following World War II marked a decisive turning point in the trajectory of phage therapy in Western medicine. Despite the promising results bacteriophages had demonstrated prior to the war as potential antibacterial agents, the decades after 1945 saw a dramatic decline in interest, funding, and scientific engagement with phage therapy in the United States and much of Western Europe. This marginalization can be attributed to a confluence of scientific, sociopolitical, and economic factors that reshaped the landscape of infectious disease treatment and research. Artistic View One of the key contributors to this decline was the overwhelming optimism surrounding the newly discovered class of antibiotics. The post-war pharmaceutical revolution brought forward a series of broad-spectrum antibiotics such as streptomycin, tetracycline, and chloramphenicol, which were viewed as miracle drugs capable o...
Read more

The Phage Therapy in the spotlight !

-
Image
Bacteriophages: Ancient Predators and the Next Frontier in Medicine In the animated documentary The Deadliest Being on Planet Earth , the Kurzgesagt team delves into the world of bacteriophages—viruses that prey exclusively on bacteria. With vibrant visuals and precise narration, the video introduces viewers to an invisible ecosystem where microscopic hunters orchestrate life-and-death dramas that shape the biosphere. These entities, though virtually unknown to the general public, may soon become central to the future of medicine. At the heart of the video lies a paradox: bacteriophages (or "phages") are among the most abundant biological entities on Earth—outnumbering all other organisms combined—yet their therapeutic potential has been largely sidelined in the antibiotic era. The video outlines the historical trajectory of phage research, spotlighting Félix d’Hérelle’s early 20th-century work and the rise of phage therapy, only to show how it was later eclipsed by the dis...
Read more

Groundbreaking achievement : Phagos raises €25m to end bacterial disease

-
Image
 Phagos raises €25m to end bacterial disease  The company holds the first authorization to market personalized veterinary phage-based treatments on EU soil  ● Founded in 2021, Phagos is ushering in a new era in the fight against bacterial disease with bacteriophages, a powerful alternative to antibiotics. Thanks to an unprecedented regulatory breakthrough and a discovery platform combining microbiology and AI, Phagos offers the first phage-based drugs for veterinary use, a market worth tens of billions of dollars. The company plans to expand further as phage therapy becomes accepted in human health.                              ● The funding round was co-led by CapAgro, Hoxton Ventures, CapHorn, and Demeter alongside Acurio Ventures, Citizen Capital, Entrepreneur First, Founders Capital, and Station F.  ● Objectives: deploy veterinary treatments in the field, develop the next generation of pat...
Read more